Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Overview | Financials
Company Name Kymera Therapeutics, Inc.
Symbol KYMR
Currency USD
Price 45.4
Market Cap 2,894,504,240
Dividend Yield 0%
52-week-range 9.6 - 50.185
Industry Biotechnology
Sector Healthcare
CEO Dr. Nello Mainolfi M.D., Ph.D.
Website https://www.kymeratx.com

An error occurred while fetching data.

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis

Related Stocks

TransMedics Group, Inc. logo

TransMedics Group, Inc.

TMDX

139.88 USD

NanoString Technologies, Inc. logo

NanoString Technologies, Inc.

NSTG

0.105 USD

Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc.

ORGO

2.47 USD

Health Catalyst, Inc. logo

Health Catalyst, Inc.

HCAT

7.29 USD

AngioDynamics, Inc. logo

AngioDynamics, Inc.

ANGO

7.17 USD

Alphatec Holdings, Inc. logo

Alphatec Holdings, Inc.

ATEC

6.415 USD

Alector, Inc. logo

Alector, Inc.

ALEC

4.85 USD

Cue Health Inc. logo

Cue Health Inc.

HLTH

0.043 USD

Financials

Numbers are in millions USD

Numbers are in millions USD